Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat in Non-Dialysis Subjects Evaluating Hemoglobin (Hgb) and Quality of Life (ASCEND-NHQ)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 614 participants.
Also called NCT03409107
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 614 participants
- Sponsor
- Registry
-
NCT03409107 -
2017-002270-39
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Brazil, Canada, France, Italy, Mexico, Poland, Romania, Russia, South Korea, Spain, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT03409107. Randomized; double masking; primary purpose treatment. Start 2018-03-05 (actual); primary completion 2020-10-07 (actual). Results posted on 2021-11-03.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat in Non-Dialysis Subjects Evaluating Hemoglobin (Hgb) and Quality of Life (ASCEND-NHQ)
- Condition
- Anaemia
- Intervention (Drug)
- Daprodustat (GSK1278863)
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Iron therapy
- Lead sponsor
- GlaxoSmithKline
Record details
- Record id
cardio:ct-nct03409107- Content hash
6a168dc4ece9140f4d5100c5d7169a149ad65f1d8c19df6e06921008b23dd9dc